News

According to Novo Nordisk, degludec reduces the risk of nocturnal hypoglycemia more than 35% compared with Lantus. Bloomberg.com has quoted Novo Nordisk chief science officer Mads Krogsgaard Thomsen

The recall is a consequence of Health Canada’s Good Manufacturing Practices (GMP) inspection at the company’s Laval manufacturing site where deficiencies in the production line were detected. Possible

Protect still retains the patents related to abuse deterrent and once daily gastro-retentive drug delivery platforms and the corresponding three other ongoing projects. In the near term, Protect

Bioject provides support for efforts to advance clinical research of intradermal delivery of vaccines in developing-country immunization programs to advance the use of DSJIs, reducing risks associated with

mPhase claims that its Smart Surface technology has potential applications within drug delivery systems, lab-on-a-chip analytic systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. The

The decision to start these facilities signifies PRA’s commitment to meet the rising demand for services in the Middle East and Eastern Europe. The aim is to accommodate

Larazotide acetate, a tight junction modulator, is progressing towards a Phase IIb clinical trial for the treatment of celiac disease. Cephalon will pay Alba a $7m upfront option

RADIANT-3, a prospective, double-blind, randomized, parallel group, placebo-controlled, multicenter study, examined the efficacy and safety of everolimus plus BSC versus placebo plus BSC in 410 patients with advanced,

Orexigen adopted this course of action following the receipt of complete response letter from the US Food and Drug Administration on 31 January 2011 regarding the new drug